Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial

被引：16

作者：

Bug, Gesine ^{[1
]}

Burchert, Andreas ^{[2
]}

Wagner, Eva-Maria ^{[3
]}

Kroeger, Nicolaus ^{[4
]}

Jedlickova, Zuzana ^{[1
]}

Gueller, Saskia ^{[1
]}

Metzelder, Stephan ^{[5
]}

Wolf, Andrea ^{[1
]}

Bader, Peter ^{[6
]}

Huenecke, Sabine ^{[6
]}

Serve, Hubert ^{[7
]}

Ottmann, Oliver G. ^{[8
]}

机构：

[1] Univ Hosp Frankfurt, Dept Med 2, Hematol Oncol, Frankfurt, Germany

[2] Univ Klinikum Giessen & Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany

[3] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med Hematol Oncol & Pneumol 3, D-55122 Mainz, Germany

[4] Univ Hosp Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

[5] Univ Giessen & Marburg, Med Ctr, Univ Marburg, Dept Hematol,Oncol,Immunol, Marburg, Germany

[6] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Hosp Children & Adolescents, Div Stem Cell Transplantat & Immunol, D-60054 Frankfurt, Germany

[7] Goethe Univ Hosp Frankfurt, Dept Med 2, Hematol Oncol, Frankfurt, Germany

[8] Cardiff Univ, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales

来源：

关键词：

D O I：

10.1182/blood.V126.23.4344.4344

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3